AbundantlyMari

Longevity gets expensive very quickly when novelty replaces hierarchy.

The modern version arrives beautifully dressed: a premium blood panel, an algorithmic age score, a supplement protocol with its own travel case, a recovery device, a peptide conversation and a subscription that promises to notice what ordinary healthcare missed.

Curiosity is not the problem. Many emerging tools are genuinely interesting. Some will become useful. A few already are—when they answer the right question for the right person.

The problem is sequence.

The short answer: spend first on the parts of health that are broadly useful, repeatable and capable of changing meaningful outcomes. Add measurement when it can change a decision. Add treatment when there is a defined reason. Let expensive or experimental interventions earn their place last.

This is not a hierarchy of virtue. It is a hierarchy of confidence, consequence and return.

Level 1: The foundations that do not photograph particularly well

Sleep, regular movement, strength, cardiovascular fitness, adequate nourishment, social connection, preventive care and avoiding nicotine are not glamorous because they are familiar. Familiarity has not made them biologically irrelevant.

The World Health Organization recommends that adults undertake regular physical activity, including 150–300 minutes of moderate-intensity aerobic activity—or the equivalent vigorous activity—each week, plus muscle-strengthening activity on at least two days. The American Heart Association's Life's Essential 8 places diet, physical activity, nicotine exposure and sleep alongside blood pressure, blood glucose, cholesterol and weight as central measures of cardiovascular health.

These frameworks are not a personalised prescription, nor are they a demand for perfect compliance. They are a useful correction to a market that can make foundational care seem almost embarrassingly unsophisticated.

Level 1 may look like:

• finding a form of movement your joints, schedule and actual temperament can tolerate;
• protecting enough time for sleep before buying a device to score the sleep you are not allowing;
• building or preserving strength rather than treating thinness as a synonym for health;
• eating in a way that is nutritionally adequate and workable beyond an unusually motivated Tuesday;
• knowing the blood pressure, glucose and cholesterol information that is relevant to you;
• keeping up with clinician-recommended screenings, vaccinations, dental care and follow-up;
• creating reliable social contact, not merely accumulating messages.

That last item deserves more than a polite footnote. Your Longevity Plan Needs More Tuesday-Night Dinner explores why ordinary, reciprocal connection belongs in longevity infrastructure without pretending that dinner is medicine.

The phrase foundations first can become unfair when it ignores disability, caregiving, financial limits, unsafe neighbourhoods, food access, shift work or the simple fact that a body may not cooperate with a generic plan. Level 1 is not a purity test. It means addressing the largest modifiable gaps available to you, with the support and adaptations you need.

It also means resisting an expensive form of procrastination: buying precision around a problem whose main constraint is already visible.

Level 2: Measurement that earns the right to exist

Data is useful when it sharpens a decision. It becomes theatre when it merely gives uncertainty a more expensive vocabulary.

Before paying for a test, tracker or dashboard, write one sentence:

If this result is X, I will do Y. If it is not, I will do Z.

If neither branch changes, the information may be interesting without being useful.

Level 2 can include validated home blood-pressure monitoring, clinician-recommended laboratory work and screening, training records, symptom logs or wearable trends that answer a defined question. It does not mean ordering every available biomarker and then asking the internet to assemble the results into a diagnosis.

The distinction matters because testing is not neutral. Results can be falsely reassuring, falsely alarming, difficult to interpret or capable of launching further procedures that carry their own costs and risks. The FDA notes that some direct-to-consumer tests are reviewed before marketing and others are not; it advises consumers to understand a test's limits and discuss health-related decisions with a qualified professional.

Start with the question, not the panel:

• What decision could this information change?
• Is the method analytically and clinically valid for that use?
• What is the ordinary medical route for investigating this concern?
• Who will interpret an unexpected result?
• What follow-up cost begins if the number is abnormal—or simply ambiguous?

This is the measurement version of Wellness Is a Strategy Problem: more information is not automatically better prioritisation. For consumer technology, the companion guide Before You Buy Another Wellness Device, Ask These Seven Questions applies the same standard to accuracy, privacy, subscription costs and real-life fit.

Level 3: Targeted care for a defined problem

Once there is a clear need, the hierarchy becomes personal.

Level 3 is where appropriately chosen physical therapy, nutrition support, mental-health care, medication, menopause care, hormone-therapy conversations or condition-specific treatment may belong. These are not “less natural” intrusions into a pure wellness plan. They are interventions with indications, contraindications, trade-offs and monitoring needs.

The keyword is targeted.

A treatment deserves a defined purpose: reduce a symptom, manage a diagnosed condition, improve function, prevent a known risk or restore something a clinician has determined is missing. The right choice depends on health history, current medicines, age and stage, preferences, access and the quality of the alternatives. That is why a hormone protocol, prescription medicine or injectable does not belong in a universal longevity stack copied from somebody else's morning routine.

Targeted care also deserves an exit or review point:

• What outcome are we trying to improve?
• When should improvement reasonably appear?
• What monitoring is appropriate?
• Which adverse effects or changes require contact with the prescriber?
• When will we decide whether to continue, change or stop?

This is not anti-intervention. It is pro-reason. A well-chosen treatment can be far more valuable than years of buying adjacent products while leaving the actual problem untreated.

Level 4: Emerging, expensive and expected to make a proper case

Now we arrive at the part of longevity culture with the most flattering lighting.

Peptides, novel supplement combinations, premium biological-age testing, recovery devices, extensive executive panels and membership longevity clinics may sit here. The category is deliberately broad because regulatory status, evidence, risk and usefulness can differ enormously from one product or intervention to another.

“Peptide,” for example, describes a type of molecule—not a guarantee of safety, efficacy or approval. Some peptide medicines are FDA-approved for specific uses. That does not confer legitimacy on every product marketed with the same fashionable word. Compounded drugs may meet an important patient need, but the FDA does not approve them or review their safety, effectiveness and quality before marketing. Products sold as “research use only” are not transformed into suitable human treatments by an attractive telehealth page.

Premium testing deserves the same discipline. A biological-age result may be interesting, but ask whether the method is validated, whether a change exceeds normal measurement variation, and whether the answer alters care beyond what standard risk factors already suggest.

Novel supplements and devices should face The Supplement Cabinet Audit and the claim-literacy questions in A Beautiful Claim Is Still a Claim. “Clinically studied” is not a complete sentence. Neither is “used by longevity doctors.”

Before Level 4 receives a budget, ask:

1. What precise outcome am I buying? Not “optimisation”—a result I could recognise or measure.
2. How strong and relevant is the evidence? Human data, the population studied, the comparator, effect size, duration and conflicts of interest all matter.
3. What is the regulatory status of this exact product and use? Approval of one molecule, device function or indication does not spread across an entire category.
4. What are the risks and unknowns? Include interactions, contamination, false reassurance, incidental findings and delayed appropriate care.
5. What is the full cost? Consultation, testing, subscription, repeat treatment, travel, monitoring and the attention required to maintain it.
6. What simpler option has not yet been tried? More complex is not automatically more advanced.
7. What would make me stop? A responsible experiment has a boundary.

If a provider cannot tolerate these questions, that tells you something before the treatment tells you anything.

The AbundantlyMari rule: do not confuse access with priority

Having the money to buy an intervention does not make it the next best use of the money.

A longevity budget has opportunity costs. The premium test may compete with physiotherapy that would make movement possible. A year's supplement subscription may cost more than dental treatment, a sleep evaluation, strength coaching, nourishing food, time-saving support or the co-pay for an overdue medical visit. The fashionable option is not always wasteful—but it must compete honestly with what the same resources could improve elsewhere.

At AbundantlyMari, the order is Evidence, Experience and Economics:

• Evidence: How confident should we be, and where does uncertainty remain?
• Experience: Can this work inside the reader's body, capacity and ordinary week?
• Economics: Does the likely benefit justify the money, maintenance and alternatives displaced?

The more experimental the intervention, the more disciplined the question should become.

Do not spend Level 4 money while ignoring the Level 1 problem that keeps sending the bill.

That does not mean waiting until life is perfect before exploring anything interesting. Perfection is not the admission price. It means knowing which level you are funding, why you are funding it and what you reasonably expect in return.

Longevity is not a shopping category. It is the compounding effect of wise foundations, useful measurement, targeted care and a very selective relationship with novelty.

Sources and further reading

• World Health Organization: Physical activity
• American Heart Association: Life's Essential 8
• U.S. Office of Disease Prevention and Health Promotion: Get Screened
• U.S. Food and Drug Administration: Direct-to-Consumer Tests
• U.S. Food and Drug Administration: Understanding the Risks of Compounded Drugs

This article is educational and is not medical advice. It does not recommend any individual test, medication, hormone therapy, peptide, supplement or treatment. Decisions about symptoms, screening, diagnosis, prescriptions, compounded drugs and hormone therapy should be made with an appropriately qualified healthcare professional who knows your history. Seek timely care for new, severe, persistent or concerning symptoms. See the AbundantlyMari editorial and wellness disclaimer.